drugset / Trial / NCT04807309

PRETELL: PREvention of TELomere-related Complications After Lung Transplant

NCT04807309

Phase 1/2 Withdrawn Brigham and Women's Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

To evaluate the safety and efficacy of Danzol in lung transplant recipients with short telomeres. Subjects with short telomeres recipient of lung transplant, will be randomized in the first month post-transplant to either placebo or Danazol (200mg bid) in a 2:1 ratio.

Timeline

Start
2021-01-01
Primary completion
2021-11-20
Completion
2022-01-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Danazol Other / unclassified 200 mg Oral

Indications